FINWIRES · TerminalLIVE
FINWIRES

加拿大皇家银行将高力国际集团的目标股价从160美元下调至155美元,但维持“跑赢大盘”评级。

By

-- 在Colliers International Group (CIGI.TO, CIGI)公布第一季度财务业绩后,加拿大皇家银行资本市场(RBC Capital Markets)维持对该公司股票的“跑赢大盘”评级,并将目标股价从160美元下调至155美元。 RBC将第一季度业绩描述为“营收强劲,但利润波动”。 RBC指出:“整体调整后息税折旧摊销前利润率(AEBITDA)下降67个基点至9.5%,主要原因包括:1) CIGI一直在加大招聘和IT投入,以提高商业地产(CRE)业务的人工智能(AI)效率;2) 外包业务增长放缓;3) 工程部门在住宅开发和电信终端市场的利用率下降;4) 欧洲税率高于预期;5) 投资管理(IM)业务整合至Harrison Street平台,这此前已有详细说明。” RBC表示,尽管维持了2026年的业绩指引,但该指引依赖于下半年强劲的业绩表现。 CM和租赁业务似乎有望实现“强劲的收入增长”,预计2026年CM业务增长25%,租赁业务增长8%。RBC预计,这些增长将在下半年更充分地转化为EBITDA,与去年同期情况类似。报告还指出,受伊朗战争的影响,欧洲和亚太地区的增长“可能有所放缓”,但北美地区“尽管利率上升,依然保持强劲”。 RBC在2026年5月5日的一份报告中表示:“鉴于宏观经济的不确定性以及人工智能持续带来的影响(在这种‘有罪推定’的环境下,人们往往被假定有罪),CIGI今天的股价走势表明,市场对业绩波动不定的季度报告和业绩指引缺乏耐心。” RBC仍然认为,即使按照RBC更为保守的2026年估值(即每股收益13倍,调整后EBITDA 10.5倍),对于“有耐心的投资者”而言,CIGI仍然具有“良好的投资价值”。 RBC补充道:“我们新的目标价为155美元(-3%),基于12.5倍的预期AEBITDA倍数,其中CRE为11倍,工程为12倍,IM为15倍。维持运营价格不变。”

Price: $137.23, Change: $+5.09, Percent Change: +3.85%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL